Business Context and Reporting Period
Oramed Pharmaceuticals Inc. filed this Form 8-K on November 8, 2012, reporting events occurring between November 2 and November 5, 2012. The company, incorporated in Delaware with principal offices in Jerusalem, Israel, executed a series of private placements to raise capital through the sale of units consisting of common stock and warrants.
Key Financial Metrics and Capital Raised
- Total Capital Raised: Approximately $684,418 from two primary private placement transactions reported in this filing.
- Transaction 1 (Nov 2, 2012): Sold 1,444,373 units at $0.37 per unit for total consideration of $534,418. This included a $50,000 investment by Leonard Sank, a company director.
- Transaction 2 (Nov 5, 2012): Sold 405,405 units to Regals Fund LP at $0.37 per unit for approximately $150,000.
- Unit Structure: Each unit comprises one share of common stock and a five-year warrant to purchase 0.50 shares at an exercise price of $0.50.
- Additional Issuances: The company issued 13,514 shares and related warrants as finder's fees and previously issued 2,390,057 shares to D.N.A Biomedical Solutions Ltd. on October 30, 2012.
- Other Metrics: The filing does not provide data on revenue, profit, cash flow, operating margins, or existing debt levels.
Material Changes and Warrant Adjustments
Significant amendments were made to existing warrants held by Regals Fund LP due to the recent private placements and a transaction with D.N.A Biomedical Solutions Ltd.:
- Exercise Price Reduction: The exercise price for Regals' prior warrant was reduced from $0.50 to $0.37, and subsequently to $0.3138.
- Share Count Increase: The number of shares issuable upon exercise of Regals' warrant increased from 2,187,500 to 2,956,081, and further to 3,485,500.
- Ownership Cap Removal: The limitation restricting Regals from holding more than 9.9% of outstanding shares was deleted.
- Anti-Dilution Rights: Regals was granted the right to maintain its percentage ownership in future issuances, provided it holds at least 5% of outstanding common stock.
Outlook, Risks, and Unusual Items
The filing focuses on capital raising activities and does not contain management commentary on future business outlook, operational risks, or contingencies beyond the standard disclosure of unregistered securities sales. The securities were sold under exemptions for "offshore transactions" (Regulation S) or private placements to "accredited investors" (Rule 506 of Regulation D). No unusual items or non-recurring charges were disclosed in this report.
Investor Verification Checklist
- Verify the total number of outstanding shares and warrants post-issuance to assess dilution impact.
- Confirm the specific terms of the anti-dilution provisions granted to Regals Fund LP.
- Review the company's cash position and burn rate to determine the runway provided by the $684,418 raised.
- Check for any subsequent filings regarding the use of proceeds from these private placements.
- Validate the status of the D.N.A Biomedical Solutions Ltd. transaction and its impact on the company's balance sheet.